ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1744

Serum Sickness Following Rituximab Treatment of Childhood-Onset SLE: A Single Center Experience

Ugo Awa1, Marietta De Guzman 2 and Eyal Muscal 3, 1Baylor College of Medicine/Texas Children's Hospital, Houston, 2Baylor College of Medicine/Texas Children's Hospital, Houston, TX, 3Baylor College of Medicine, Houston, TX

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Abstracts, juvenile SLE, rituximab and serum sickness

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Childhood-onset SLE (cSLE) is an autoimmune disease characterized by multiorgan involvement often necessitating a variety of immunolytic and immunomodulatory therapies to achieve adequate disease control and remission. One of these agents, in which effectiveness and safety has been well defined, is Rituximab, a chimeric monoclonal antibody that binds to CD20 expressed on B lymphocytes initiating B cell lysis and subsequent depletion of antibody burden. An uncommon adverse reaction is serum sickness (SS), an immune complex-mediated (“type III”) hypersensitivity characterized as a triad of rash, fever and polyarthritis/arthralgias. Though not commonly documented, rituximab-induced SS has been noted in patients with underlying autoimmune diseases, and reported disorders including Sjogren’s syndrome, chronic ITP, and rheumatoid arthritis.

Methods: With a local IRB approval, a retrospective review of the electronic health records of patients with cSLE from July 2011 to May 2019 was performed. Patients who developed SS following Rituximab treatment were included. Descriptive analyses were done to ascertain similarities amongst the patients, possible risk factors for the development of SS, response to treatment and use of other anti-CD20 medication use.

Results: At the time of this study, there were 210 cSLE patients being actively followed, 20 patients had received Rituximab as part of treatment. 6 patients developed SS after Rituximab treatment, 1 was excluded due to incomplete record. Of the 5 patients, 4 were female.  The mean age of patients was 16.6 years old.  All 5 were Hispanic.  Mean disease duration was 3.8 years (Range: 2 to 6 years).  Mean SLEDAI score at time of Rituximab treatment was 6.6 (Range: 4 to 11); 2 patients had polyclonal hypergammaglobulinemia and cSLE treatment included steroids (4/5), MMF (2/5), hydroxychloroquine (5/5).  3 patients had history of prior rituximab treatment with a mean dose of 858 mg/dose (575mg/dose to 1000 mg/dose) and mean interval from previous to most recent dose of 17.3 months. Mean time for drug exposure to SS manifestation was 9.8 days (Range: 7-13 days). Manifestations of SS included fever (4/5), acute polyarthritis (4/5), and rash (5/5). Anti-rituximab antibody was not determined at time of SS diagnosis. All patients required increased dose of glucocorticoids. 2 required hospitalization. 2 patients received and tolerated alternative B-cell depletion (ofatumumab).

Conclusion: We described a small cohort of cSLE who developed SS following rituximab treatment.  It is important to recognize this adverse reaction as SS manifestations mimic that of active SLE features.


Disclosure: U. Awa, None; M. De Guzman, None; E. Muscal, None.

To cite this abstract in AMA style:

Awa U, De Guzman M, Muscal E. Serum Sickness Following Rituximab Treatment of Childhood-Onset SLE: A Single Center Experience [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/serum-sickness-following-rituximab-treatment-of-childhood-onset-sle-a-single-center-experience/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-sickness-following-rituximab-treatment-of-childhood-onset-sle-a-single-center-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology